AUPH Research and Charts

AUPH - Aurinia Pharmaceuticals Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2024-10-31 (Delayed quote data 2025-04-03)

Last 8.05	Change ⇓ -0.14 (-1.71%)	Volume 1,340,665
	Open 7.89	High 8.08	Low 7.88

8EMA (Daily) 8.21	40EMA (Daily) 8.21	50EMA (Daily) 8.20	STO (Daily) 23.806	MACD Hist (Daily) -0.090
8EMA (Weekly) 8.161	40EMA (Weekly) 7.75	50EMA (Weekly) 7.68	STO (Weekly) 50.691	MACD Hist (Weekly) -0.101


Company Profile
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States followed by China.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.